Abstract: A time-synchronous lattice-constrained search algorithm is developed and used to process a linguistic model of speech that has a long-contextual-span capability. In the algorithm, hypotheses are represented as traces that include an indication of a current frame, previous frames and future frames. Each frame can include an associated linguistic unit such as a phone or units that are derived from a phone. Additionally, pruning strategies can be applied to speed up the search. Further, word-ending recombination methods are developed to speed up the computation. These methods can effectively deal with an exponentially increased search space.

Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

Abstract: An automatic speech recognition system recognizes user changes to dictated text and infers whether such changes result from the user changing his/her mind, or whether such changes are a result of a recognition error. If a recognition error is detected, the system uses the type of user correction to modify itself to reduce the chance that such recognition error will occur again. Accordingly, the system and methods provide for significant speech recognition learning with little or no additional user interaction.

Abstract: The invention provides novel oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif and the use of such compounds in the prevention and treatment of TLR-medicated diseases. These oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif have one or more chemical modifications in the immune stimulatory motif, which would be immune stimulatory but for the modification.

Abstract: A method of forming a shareable filler model (shareable model for garbage words) from a word n-gram model is provided. The word n-gram model is converted into a probabilistic context free grammar (PCFG). The PCFG is modified into a substantially application-independent PCFG, which constitutes the shareable filler model.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.

Abstract: A computer-implemented method is disclosed for improving the accuracy of a directory assistance system. The method includes constructing a prefix tree based on a collection of alphabetically organized words. The prefix tree is utilized as a basis for generating splitting rules for a compound word included in an index associated with the directory assistance system. A language model check and a pronunciation check are conducted in order to determine which of the generated splitting rules are mostly likely correct. The compound word is split into word components based on the most likely correct rule or rules. The word components are incorporated into a data set associated with the directory assistance system, such as into a recognition grammar and/or the index.

Abstract: A novel system integrates speech recognition and semantic classification, so that acoustic scores in a speech recognizer that accepts spoken utterances may be taken into account when training both language models and semantic classification models. For example, a joint association score may be defined that is indicative of a correspondence of a semantic class and a word sequence for an acoustic signal. The joint association score may incorporate parameters such as weighting parameters for signal-to-class modeling of the acoustic signal, language model parameters and scores, and acoustic model parameters and scores. The parameters may be revised to raise the joint association score of a target word sequence with a target semantic class relative to the joint association score of a competitor word sequence with the target semantic class. The parameters may be designed so that the semantic classification errors in the training data are minimized.

Abstract: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.

Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.

Abstract: A method of automatically capitalizing text utilizes a capitalization model. The capitalization model is trained from data that is taken from documents associated with a particular user. In particular, documents that are authored by the user such as e-mails, are used to train the model.

Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.

Abstract: An ink for forming CIGS photovoltaic cell active layers is disclosed along with methods for making the ink, methods for making the active layers and a solar cell made with the active layer. The ink contains a mixture of nanoparticles of elements of groups IB, IIIA and (optionally) VIA. The particles are in a desired particle size range of between about 1 nm and about 500 nm in diameter, where a majority of the mass of the particles comprises particles ranging in size from no more than about 40% above or below an average particle size or, if the average particle size is less than about 5 nanometers, from no more than about 2 nanometers above or below the average particle size. The use of such ink avoids the need to expose the material to an H2Se gas during the construction of a photovoltaic cell and allows more uniform melting during film annealing, more uniform intermixing of nanoparticles, and allows higher quality absorber films to be formed.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.

Abstract: Described is a technology by which a maximum entropy (MaxEnt) model, such as used as a classifier or in a conditional random field or hidden conditional random field that embed the maximum entropy model, uses continuous features with continuous weights that are continuous functions of the feature values (instead of single-valued weights). The continuous weights may be approximated by a spline-based solution. In general, this converts the optimization problem into a standard log-linear optimization problem without continuous weights at a higher-dimensional space.

Abstract: A novel system for speech recognition uses differential cepstra over time frames as acoustic features, together with the traditional static cepstral features, for hidden trajectory modeling, and provides greater accuracy and performance in automatic speech recognition. According to one illustrative embodiment, an automatic speech recognition method includes receiving a speech input, generating an interpretation of the speech, and providing an output based at least in part on the interpretation of the speech input. The interpretation of the speech uses hidden trajectory modeling with observation vectors that are based on cepstra and on differential cepstra derived from the cepstra. A method is developed that can automatically train the hidden trajectory model's parameters that are corresponding to the components of the differential cepstra in the full acoustic feature vectors.

Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.